Journal of Gastroenterology

, Volume 39, Issue 1, pp 34–40

Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine

Authors

  • Marie Matsuda
    • Research Institute for HepatologyToranomon Branch Hospital
  • Fumitaka Suzuki
    • Department of GastroenterologyToranomon Hospital
  • Yoshiyuki Suzuki
    • Department of GastroenterologyToranomon Hospital
  • Akihito Tsubota
    • Department of GastroenterologyToranomon Hospital
  • Norio Akuta
    • Department of GastroenterologyToranomon Hospital
  • Tetsuya Hosaka
    • Department of GastroenterologyToranomon Hospital
  • Takashi Someya
    • Department of GastroenterologyToranomon Hospital
  • Masahiro Kobayashi
    • Department of GastroenterologyToranomon Hospital
  • Satoshi Saitoh
    • Department of GastroenterologyToranomon Hospital
  • Yasuji Arase
    • Department of GastroenterologyToranomon Hospital
  • Junko Satoh
    • Research Institute for HepatologyToranomon Branch Hospital
  • Kimiko Takagi
    • Research Institute for HepatologyToranomon Branch Hospital
  • Mariko Kobayashi
    • Research Institute for HepatologyToranomon Branch Hospital
  • Kenji Ikeda
    • Department of GastroenterologyToranomon Hospital
  • Hiromitsu Kumada
    • Department of GastroenterologyToranomon Hospital
Article

DOI: 10.1007/s00535-003-1242-4

Cite this article as:
Matsuda, M., Suzuki, F., Suzuki, Y. et al. J Gastroenterol (2004) 39: 34. doi:10.1007/s00535-003-1242-4

Background

Lamivudine is used for the treatment of chronic hepatitis B (CH-B), and exhibits excellent antiviral activity. However, longterm administration increases the likelihood of the emergence of resistant viruses, with an accompanying relapse of hepatitis. However, recent studies have reported lamivudine-resistant viruses in patients with CH-B before such treatment. The aim of this study was to investigate whether YMDD mutants occur in nature.

Methods

The existence of lamivudine-resistant viruses was examined in 20 asymptomatic carriers of hepatitis B virus (ASC), 10 patients who lost hepatitis B surface antigen (HBsAg) during follow-up and in 20 lamivudine-treated patients with and without breakthrough hepatitis. Both polymerase chain reaction (PCR) restriction fragment length polymorphism and SMITEST hepatitis B virus (HBV)-YMDD mutation detection methods were used to detect resistant viruses.

Results

No YMDD mutants were detected in the sera of the 20 ASC at the initial and final medical examinations, nor were YMDD mutants detected in sera collected at the initial medical examination, about 6 months before, or immediately after the loss of HBsAg in the 10 patients. In the 20 patients treated with lamivudine, YMDD mutants were not detected in any of them before treatment, whereas mutants were detected in the sera of 10 patients during treatment.

Conclusions

Our results suggest that lamivudine-resistant YMDD mutant viruses were present in a few patients with HBV infection who before they have been treated with lamivudine.

Key words

hepatitis B viruslamivudineYMDD mutant

Copyright information

© Springer-Verlag Tokyo 2004